Filtered By:
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 12509 results found since Jan 2013.

Feasibility, safety and cost of outpatient management of acute minor ischaemic stroke: a population-based study
Conclusion Outpatient management of clinic-referred minor stroke is feasible and may be as safe as inpatient care. Rates of early hospital admission and recurrent stroke were low and uptake and maintenance of secondary prevention was high.
Source: Journal of Neurology, Neurosurgery and Psychiatry - February 15, 2013 Category: Neurosurgery Authors: Paul, N. L. M., Koton, S., Simoni, M., Geraghty, O. C., Luengo-Fernandez, R., Rothwell, P. M. Tags: Stroke Cerebrovascular disease Source Type: research

Abstract 12: Evaluation of Medical Costs Associated with Use of Novel Oral Anticoagulants Compared with Warfarin Among Nonvalvular Atrial Fibrillation Patients with Moderate and High Stroke Risk Concurrent I Session B: Oral Abstract Presentations on Stroke Topics
Conclusions: Of the three NOACs, apixaban demonstrated greater medical cost reductions relative to warfarin among NVAF patients at moderate and high stroke risk. The medical cost reduction associated with apixaban use instead of warfarin was greater for NVAF patients at higher stroke risk vs. those at moderate stroke risk and was driven primarily by higher absolute reductions in clinical event rates for major bleeding, stroke and systemic embolism.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Deitelzweig, S., Amin, A., Jing, Y., Makenbaeva, D., Wiederkehr, D., Lin, J., Graham, J. Tags: Concurrent I Session B: Oral Abstract Presentations on Stroke Topics Source Type: research

Stroke and Major Bleeding Risk in Elderly Patients Aged >=75 Years With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project Clinical Sciences
Conclusions— Elderly patients with AF have a higher risk of stroke and bleeding, but the benefits of VKA therapy for stroke/thromboembolism or mortality were present regardless of increasing age.
Source: Stroke - December 22, 2014 Category: Neurology Authors: Lip, G. Y. H., Clementy, N., Pericart, L., Banerjee, A., Fauchier, L. Tags: Health policy and outcome research Clinical Sciences Source Type: research

Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Objective: To update the 1998 American Academy of Neurology practice parameter on stroke prevention in nonvalvular atrial fibrillation (NVAF). How often do various technologies identify previously undetected NVAF? Which therapies reduce ischemic stroke risk with the least risk of hemorrhage, including intracranial hemorrhage? The complete guideline on which this summary is based is available as an online data supplement to this article. Methods: Systematic literature review; modified Delphi process recommendation formulation. Major conclusions: In patients with recent cryptogenic stroke, cardiac rhythm monitoring probabl...
Source: Neurology - February 24, 2014 Category: Neurology Authors: Culebras, A., Messe, S. R., Chaturvedi, S., Kase, C. S., Gronseth, G. Tags: All Cerebrovascular disease/Stroke SPECIAL ARTICLE Source Type: research

Effectiveness and safety of antiplatelet in stroke patients with end‐stage renal disease undergoing dialysis
ConclusionsAntiplatelet therapy, especially aspirin, still offers safe and effective treatment for ischemic stroke prevention in patients with end‐stage renal disease undergoing dialysis.
Source: International Journal of Stroke - February 1, 2014 Category: Neurology Authors: Chung‐Yu Chen, Kun‐Tai Lee, Charles Tzu‐Chi Lee, Wen‐Ter Lai, Yaw‐Bin Huang Tags: Research Source Type: research

Impact of Prestroke Selective Serotonin Reuptake Inhibitor Treatment on Stroke Severity and Mortality Brief Reports
Conclusions— Prestroke SSRI use is associated with increased stroke severity and mortality in patients with hemorrhagic stroke. Although prestroke depression in itself may increase stroke severity and mortality, this was not found in SSRI users with ischemic stroke.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Mortensen, J. K., Larsson, H., Johnsen, S. P., Andersen, G. Tags: Platelet function inhibitors, Acute Cerebral Hemorrhage, Acute Cerebral Infarction, Neuroprotectors Brief Reports Source Type: research

Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial Stroke
Conclusions High BP measurement at any point during the trial was independently associated with a substantially higher risk of stroke or systemic embolism. These results strongly support efforts to treat elevated BP as an important strategy to optimally lower risk of stroke in patients with AF. Clinical Trial Registration URL: https://ClinicalTrials.gov/. Unique identifier: NCT00412984.
Source: JAHA:Journal of the American Heart Association - December 1, 2015 Category: Cardiology Authors: Rao, M. P., Halvorsen, S., Wojdyla, D., Thomas, L., Alexander, J. H., Hylek, E. M., Hanna, M., Bahit, M. C., Lopes, R. D., De Caterina, R., Erol, C., Goto, S., Lanas, F., Lewis, B. S., Husted, S., Gersh, B. J., Wallentin, L., Granger, C. B., the Apixaban Tags: Stroke Source Type: research

Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE
Conclusions: Clopidogrel–aspirin treatment may have a benefit of reducing stroke risk outweighing the potential risk of increased bleeding especially within the first 2 weeks compared with aspirin alone in patients with minor stroke or TIA. Clinicaltrials.gov identifier: NCT00979589. Classification of evidence: This study provides Class II evidence that for patients with minor stroke or TIA, the reduction of stroke risk from clopidogrel plus aspirin within the first 2 weeks outweighs the risk of bleeding compared with aspirin alone.
Source: Neurology - May 15, 2017 Category: Neurology Authors: Pan, Y., Jing, J., Chen, W., Meng, X., Li, H., Zhao, X., Liu, L., Wang, D., Johnston, S. C., Wang, Y., Wang, Y., On behalf of the CHANCE investigators Tags: All Cerebrovascular disease/Stroke, Clinical trials Randomized controlled (CONSORT agreement) ARTICLE Source Type: research

The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double‐blind, placebo‐controlled multicenter trial
ConclusionThe SPAD trial is the first study to evaluate the safety and efficacy of dual antiplatelet agents, aspirin plus cilostazol, in comparison with aspirin alone in patients with both ischemic stroke or TIA and PAD. Results from this trial will provide important information on the merit of adding cilostazol to aspirin for slowing down progression of atherosclerosis in patients with ischemic stroke and PAD.
Source: International Journal of Stroke - November 14, 2014 Category: Neurology Authors: Jiann‐Shing Jeng, Yu Sun, Jiunn‐Tay Lee, Ruey‐Tay Lin, Chih‐Hung Chen, Helen L. Po, Huey‐Juan Lin, Chung‐Hsiang Liu, Ming‐Hui Sun, Mu‐Chien Sun, Chang‐Ming Chern, Li‐Ming Lien, Hou‐Chang Chiu, Han‐Hwa Hu, Hung‐Yi Chiou, Sien‐Ts Tags: Protocols Source Type: research

TALOS: a multicenter, randomized, double‐blind, placebo‐controlled trial to test the effects of citalopram in patients with acute stroke
DiscussionSSRI treatment is well tolerated and overall beneficial in the wake of stroke; it may also be neuroprotective and prevent new vascular events.
Source: International Journal of Stroke - April 8, 2015 Category: Neurology Authors: Kristian Lundsgaard Kraglund, Janne Kaergaard Mortensen, Erik Lerkevang Grove, Søren Paaske Johnsen, Grethe Andersen Tags: Protocol Source Type: research

Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis Stroke
Conclusions Long-term monotherapy was a better choice than long-term dual therapy, and cilostazol had the best risk–benefit profile for long-term secondary prevention after stroke or transient ischemic attack. More randomized controlled trials in non–East Asian patients are needed to determine whether long-term use of cilostazol is the best option for the prevention of recurrent stroke.
Source: JAHA:Journal of the American Heart Association - August 24, 2015 Category: Cardiology Authors: Xie, W., Zheng, F., Zhong, B., Song, X. Tags: Stroke Source Type: research

Neurogenesis in Stroke Recovery
Abstract Stroke, resulting from limited blood flow to the brain, is one of the most important causes of morbidity and mortality worldwide. Stroke is classified as ischemic, due to lack of blood flow, or hemorrhagic, due to bleeding. Because 87 % of strokes are classified as ischemic, this type will be the predominant focus of this review. Except for thrombolytic therapy, there is no established treatment to reduce the neurological deficits caused by ischemic stroke. Therefore, it is necessary to develop new therapeutic strategies designed to improve neurological functions after ischemic stroke. Recently, therapie...
Source: Translational Stroke Research - March 17, 2016 Category: Neurology Source Type: research

Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up
In conclusion, clopidogrel is suggested for patients with an ESRS >  3 and aspirin for patients with an ESRS ≤ 3 for the secondary prevention of noncardioembolic ischemic stroke in Chinese patients.
Source: Translational Stroke Research - December 30, 2016 Category: Neurology Source Type: research

Bleeding Complications Associated with Warfarin Treatment in Ischemic Stroke Patients with Atrial Fibrillation: A Population-Based Cohort Study
Background: Bleeding events are the major obstacle to the widespread use of warfarin for secondary stroke prevention. Previous studies have not examined the use of risk stratification scores to estimate lifetime bleeding risk associated with warfarin treatment in a population-based setting. The purpose of this study is to determine the lifetime risk of bleeding events in ischemic stroke patients with atrial fibrillation (AF) undergoing warfarin treatment in a population-based cohort and to evaluate the use of bleeding risk scores to identify patients at high risk for lifetime bleeding events.Methods: The resources of the R...
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2013 Category: Neurology Authors: Raymond C.S. Seet, Alejandro A. Rabinstein, Teresa J.H. Christianson, George W. Petty, Robert D. Brown Tags: Original Articles Source Type: research

Use of antiplatelet drugs in stroke prevention: time for a rethink?
Worldwide, 15 million people suffer stroke each year from which a third die and a further third sustain severe disability, with ischaemic events accounting for ~80% of all strokes.1 The annual estimated economic burden of stroke is 64.1 billion in Europe alone.2 While recent major investments in acute stroke services have focused on thrombolysis and hospitalisation in dedicated stroke wards, we believe that primary and secondary stroke prevention should remain of utmost importance in a disease that carries such serious permanent neurological sequelae. Antiplatelet agents such as aspirin, diypridamole or clodpidogrel are ph...
Source: Postgraduate Medical Journal - May 17, 2013 Category: Journals (General) Authors: Loke, Y. K., White, J. R., Bettencourt-Silva, J. H., Potter, J. F., Myint, P. K. Tags: GI bleeding, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Epidemiology Editorials Source Type: research